The serious Long-term 
A SURVEY OF the overall picture of the treatment of chr.onlc schizophrenic patients indicates. that the vast majority are receiving antipsychotic drug therapy. Most experts believe that drug therapy should be continued indefinitely in view of the substantial risk of relapse upon discontinuance (1). However, recent pub~i cations (2, 3) have pointed to the serious and often Irreversible complications of prolonged antipsychotic --ther-apy ... .:tar-dLY:e:1iy~la in particulai is b!io~ng recognized as a major therapeutic challenge. T is ateappearing, persistent neurological syndrome seems to be associated with the use of antipsychotic compounds. The prevalence of tardive ?yski~esia among. patients on lqng-terrrt drug therapy 1s estimated to be between 0.5% and 40% (4). Unfortunately, there has been no effective treatment for tardive dyskinesia to date.
The seriousness of the long~term complications war-rants a reexamination of the evidence in favor of longed maintenance antipsychotic therapy. ally research dealing with maintenance the;apy has focused on relapse rates. Typical evaluating the need for continued maintenance therapy compare a group of patients withdrawn phenothiazines with a group maintained on drugs. principal outcome measure is the number ~r centage of patients who show clinical deterioration. as is usually the case, a substantial number of withdrawn patients deteriorates in contrast to the continued group, it is concluded that drug is too risky and continued drug therapy is therefore sential. We feel that this approach has limit~tions . does not do justice to the complex clinical issues valved. The concept of the risk/benefit ratio, which ten governs clinical decisions, should be more attention. The clinician faced with a schizophrenic patient on maintenance antlpsv~:n<)tl!~';K.i therapy ought to consider the following issues: . I. The clinical impact of relapse. Although It IS portant to know the likelihood of patient relapse lowing antipsychotic drug withdrawal, it is just as portant to know how serious the consequenc~s o~ a relapse would be. Psychotic decompensatiOn m · ... : · employed head of a household may lead to disastrou~ psychological and ~conomic consequenc~s for a.w~o!¢ family, while the same adverse change Ill a hospital-· ized chronic patient may result in much less upheav_al. Thus drug discontinuance studies should emphasiZe -the-impact_oL_relaQse and the _ _subseqtlent-fate-of__re:---lapsed patients in addition to assessm&::relapse rat~s. In particular, suicidal, self-destructive, or assaultive behavior should be noted.
2. The benefits of continued drug therapy. A ~ost important theoretical aspect of maintenance antipsychotic therapy is whether these drugs are only prophylactic or are also therapeutic. The clinician needs to know whether by withdrawing drugs he simply deprives the patient of protection against future relapse or whether he is also depriving him of an active therapeutic agent, thereby circumventing continued . improvement. This kind of information could be obtamed if data on psychosocial functioning were reported separately for drug and placebo survivors (i.e., nonre~~~-. It is worth examining the drug discontinuance htera-
to qetermine the extent to which pubprovide .information on the clinically risk/benefit issues. In this article, we will fo-;hi:WJlhr·en:'tc patients who are nothospitalized, are the appropriate group for study ·m,•in·tpr"' as opposed to drug treatment isr.r .. ·nv•'"", inpatients are shielded from many of ~e stresses experienced by patients in the community llat might lead to relapse (5). Therefore, the study of utpatients more accurately reveals the extent to rhich drugs can protect patients from regression or deompensation under stress.
In' our discussion of outpatient antipsychotic drug fithdrawal studies, we will mention methodological ;roblems, but we will not discuss them in detail.
~VIEW OF OUTPATIENT STUDIES GEORGE GARDOS AND JONATHAN 0. COLE patients were on a low dosage (the eq..uivalent of !50 to 200 mg of CPZ per day). During 10 months, 12 of 19 placebQ patients deteriorated and 8 required rehospitalization: Only_ I patient on active medication ,got worse. The 7 placebo survivors and 23 drug survivors showed little or no change. To estimate the impact of contact with the aftercare clinic, the study included a control group of discharged schizophrenics not attending the clinic.· A follow-up inquiry with-relatives of the latter group yielded 27 usable responses, which indicated that 13 of27 patients were not doing well; 6 of these 13 were on drugs and 7 were not. Fourteen patients were apparently doing well, 6 of them on drugs and 8 not receiving phenothiazines.
Wiener and associates (I 0) withdrew medication from 41 outpatients and compared them to a randomly selected group of 42 patients who continued medication. Twenty-six of the 41 were successfully withdrawn for the 3-month study period. The only negative Tuteur and associates (6) substituted placebo for result was an increase in depression scores on the Min-:lW doses of chlorpromazine (CPZ) in 57 socially renesota Multiphasic Personality ·Inventory. However, :overed chronic female schizophrenic outpatients since the population was a_Jllixture of psychotic and etm in a drug clinic. The relapse rate was 56% neurotic patients and the drugs included meprobam~t.e N=32), compared to a rate of 13% in a similar group as well as CPZ, the results are difficult to interpr-et". ~~ents who stayed on CPZ. In 3 placebo patients, Pasamanick and associates (ll) studied home care eli@:se led to extended rehospitalization; 27 relapsed of schizophrenics under drug and placebo conditions.
iiilients recompensated within days of resuming mediAlthough this was hot·-strictly a withdrawal study, the ~;and 2 patients recompensated after a brief readfindings are rele·vant to our review. Sixty-five (83%) of
IU5&0n. No mention is made of the psychosocial ad-drug-treated p4ients as opposed to 31 (55%) of the
IISfinent of the placebo survivors. patients on plafebo were successfully maintained at ?lncaplacebo-controlled withdrawal study of chronic home for 6 to 8 months. However, the drug failure ~Yehotic outpatients by Gross (7), 50 of 98 patients · subjects spent an average of 168 days in the hospital,. ~.placebo (51%) relapsed within 6 months as opposed whereas the average stay of the placebo failures was ~<6-of 46 (l3%) in the drug-maintained control group . ..;--94 days.
~~We-ver, !Gross noted that while 50% of clinic f" In a controlled study by Engelhardt and asso@ifents who relapsed on active medication had to be ciates (12), schizophrenic outpatients were assigned to ~l!Pltalized., only 13% of drug-withdrawn relapsed CPZ, promazine, or placebo and were followed for 48 lQnts needed rehospitalization-the rest regained months. Hospitalization was required for 19.1% of 152 itahility under resumed medication. Unfortunately, CPZ patients versus 31.0% ofthe 142 placebo patients. Jt~{Stlldy population was not adequately describe.d and It was concluded that CPZ prevented rather than mere-'functioning of the placebo survivors was not ly delayed hospitalization. ,r,esented.
Leff and Wing (5) studied maintenance phenothia-. · · . ~ a~ zine therapy of acute schizophrenics who had recovsubstituted placebo for CPZ. Five patients reand showed severe social disorganization. CPZ was reinstituted, these 5 'patients imWhen placebo was reinstituted, there was re-· . indi;v~dual consistency; tp.e 5 patients again after about the same amount of time. Despite sample, this study strongly suggests conof drug response for individual patients and the possibility that a patient's past response to withdrawai can be used to predict future behavand associates (9) studied a group of r·h•~nn,,,. schizophrenics who had been disfrom a state hospital for at least I year. were randomly assigned to continued phenotherapy or to "exact replica placebo." Most suitable patients, only 35 entered the trial; s group was randomly assigned to trifluoperazine, CPZ, or placebo. During the !-year study," 12 of 15 placebo patients (80%) relapsed as opposed to 7 of the 20 drugtreated patients (35%). All 7 drug relapsers but only 6 of the 12 placebo relapsers were rehospitalized. Follow-up of the 81 patients who had not entered the trial revealed that their overall relapse rate was similar to the overall relapse rate of the study group (56.8% and 53.3%, respectively). Patients with good prognoses who were not-on phenothiazines did rather well (27.3% relapse rate), while drug patients with poor prognoses did poorly (66.7% relapse rate). These two groups had been excluded from the controlled portion of the investigation on the grounds that they had been either too well or too sick for pu1 poses of the study. Hirsch and associates (13) substituted placebo injections in half of a group of 81 chronic schizophrenics maintained on fluphenazine decanoate. The relapse rates in 9 months were 66% for placebo patients and 8% for drug patients. However, since negative responders and relapsers on fluphenazine had been screened out before the study, the authors estimated that over 30% of unselected patients probably could not be maintained on fluphenazine injections. It was noteworthy that 89% of the drug patients received only one 25-mg injection of fluphenazine decanoate monthly, which was a very low but apparently quite effective maintenance dose. The patients who relapsed on placebo were found to be very difficult to restabilize (14) .
In a controlled study of the posthospital treatment of 374 schizophrenics, Hogarty and Goldberg (15) compared CPZ with placebo and also studied the effects of "major role therapy," a form of intensive casework with rehabilitation counseling. Clinical deterioration on placebo as shown by cumulative relapse rates was substantial: 67% at the end of 1 year and. 80% at the end of 2 years. However, the corresponding relapse rates for the CPZ group also tended to be high: 31% at I year and 48% at 2 years. Approximately 75%._9f relapsers required rehospit3.l.ization (16) .
The drug relapse rates in the Hogarty and Goldberg study may be inflated, since an unknown number of patients may have discontinued medication on their own· prior to relapse. The results clearly indicate the prophylactic value of CPZ: the drug prevented relapse and probably rehospitalization in at least ~ third and possibly more of the patients. Analysis of ~ata for the survivors showed that drug-treated patients who survived in the community did not adjust any better than patients who managed to survive ori placebo (17).
DISC,USSION
The studies we revie~ed had some major deficiencies. A great deal of information was missing in terms of population characteristics, control for confounding variables, enumeration of side effects, clini--_cal assessment-of-plaeebo--st.trvi-vot's, and desc-r-iptien of the subsequent fate of relapsed patients. Never--.-theless, based .on the reported findings, we have arrived at several tentative conclusions.
A number of clinical implications can be from this conclusion. The question arises of what portion of chronic schizophrenic outpatients need to be on antipsychotics, either because would do. well without medication or because would not do well on drugs for reasons including ure to fil}d optimal drug or dose level, or toxicity. Judging by this review, the such patients may be as high as 50%.
The suggestion that as many as half of patients might not be worse off if their u•c•u••"'·'""'''-"' tipsychotic medication were withdrawn will meet with some raised eyebrows. It is well to· ber, however, that there may be a substantial ence between the efficacy of drug treatment given to patients and the theoretical drug/dosage combination. The more the actual chotic therapy approximates idealized optimal cacy, the larger the drug-placebo 9ifferences could come following drug withdrawal. The longer a has been on maintenance antipsychotic greater the likelihood that an effective combination has been found, and less the likelihood of relapse on continued While there were not adequate data in the withdrawal studies regarding length of macotherapy, it was our distinct impression lowest drug relapse rates and the largest d u"'-"''a·"'' differences were obtained in populations who on maintenance antipsychotic therapy for the time (13). Conversely, patients recently from the hospital tended to•experience higher lapse rates and smaller drug-placebo differences However, we believe that even in the most groups, a number of patients could be saved dangers of tardive dyskinesia as well as from the cial and social burdens of prolonged drug
Consequences of Relapse
. Rehospitalization rates after placebo relapse between 10 and 75%. In some studies, relapsed tients recompensated quickly following return medication._(.6, 7); in others. restabil_ization after lapse was --ctifficultiBt.-An-·int-eresting tr~rid ---from three studies, in that drug failures ' have a considerably higher rehospitalization rate placebo relapsers (5, 7, 11). The most obvious · Relapse Rates Attributable to Drug Withdrawal ~ pretation is that patients who relapse on · j . are sicker than placebo relapsers. Leff and
Since there was considerable variation in the perstudy (5) provides indirect support for this hypothe centage of patients who relapsed while on antipsychotOne of the outstanding methodological features of ic medication. the best estimate of deterioration attribstudy was the authors' ability to follow-up those utable to drug discontinuance can be obtained from able patients who did not enter the trial. drug-placebo differences. Drug-placebo differences ·in patients who were on drugs but were judged to be relapse rates in the studies cited ranged between 12% sick to be withdrawn, a substantial 67% relapse and 59%. with a median value of 40%. Therefore, one was found, confirming the clinical judgment that can conclude that for at least 40% of outpatient schizowere poor risks. · phrenics, phenothiazines are essential for survival in From the sparse data, one may tentatively infer the community.
'· · relapse following drug discontinuation can be majority of qses'by prompt resumption of drug and that the best guide to the likelihood and . of relapse and recovery is probably the 's past behavior in a similar situation (8).
in Placebo Survivors
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_\:
thiazine-induced decompensation rep~ed by Van Putten and associates (19) , wherein increased psychosis was associated with akathisia and was reversed by the administration of an anticholinergic. We believe that at least some relapses, especially during the first 4 to 6 weeks after antipsychotic withdrawal, are attributable to withdrawal emergent dyskinesia rather than to psy-. There was little information in the reviewed withchotic decompensation. ~wal studies on the comparative functioning of piaIn view of the above findings and especially in view l':su~vivors and dr~g survivors. However, none ~f of the fact that it is almost impossible to predict accu-~u d1es we have d1scussed showed placebo surv1-rately which patients will relapse when their antipsyto be doing any worse than patients maintained on chotic medication is withdrawn (I), we tentatively of-[Jigs. In fact, the studies by Leff and Wing (5) and fer the following guidelines to clinicians who wish to pgarty and associates ( 17) suggest that there might evaluate the need for continued maintenance therapy. {a subgroup of patients, albeit small, who function ~ti;er without drugs than drug-maintained patients do. ~ · ~?:'the studies we reviewed tend to support the c~~ GUIDELINES ~ton of Hogarty and Goldberg (15) :·!. ithdrawal symptoms that are commonly observed weeks after antipsychotic withdrawal to guard against n ng the fii:st 10 to 14 days after phenothiazine discholinergic withdrawal symptoms; and 4) if discussion :> · inuance have been recognized (18), but they were with the patiept reveals that he is most reluctant to be ot focused on in withdrawal studies. However, it apwithout medication, reduction to a token amount is ears that some patients who appear to deteriorate preferable to total .withdrawal. Further course of acithin a few weeks of drug withdrawal may in fact be tion would Raturally depend on what happens to the eveloping dyskinesia rather than adverse clinical patient following drug discontinuation. There are four b.ange. In an ongoing pilot study of antipsychotic major possibilities. ·ithdrawal, we have observed increased dyskinetic .
I. There may be severe relapse, with or without reovements _ m. Tofthen:rsr-s--ptaceo-o-retapsers.-trnspltalizauon. Obviously, __inLhese. situations ret~rn atients who show newly appearing dyskinetic moveto antipsychotic medication in adequate doses is intents after antipsychotic withdrawal can be assumed dicated. Perhaps a new attempt could be made at a lat-' have a covert form of persistent dyskinesia, preer date to reduce dosage or to institute drug-free weekiously suppressed by drugs and made overt by drug ends or holidays as suggested by Prien and Klett (1 ): iscontinuance.Jn our pilot study, it was quite difficult 2. In cases of Jesser clinical deterioration, the best 1 assess the relative contributions of the two conaction would probably be prompt reestablishment of . 11rrent processes-increased dyskinesia and inprevious antipsychotic therapy to achieve recompensareased psychiatric symptoms_.:.to the clinical decition. However, many of these patients may be good on to drop the patients from the study. Some patients candidates for dosage reduction, and a subsequent atppeared to react to a relatively sudden increase in tempt to reduce the dosage could be initiated. yskinesia with agitation, psychosomatic complaints, 3. If no adverse behavior change occurs, one can 11d miscellaneous symptoms seemingly unrelated to hope to have found an ideal candidate for antipsychottovement disorders. To observers such as family, fosic drug withdrawal. However, these patients should be lr parents, aftercare staff, or even physicians, these closely followed fot at least 1 year, since clinical reehavioral changes may have indicated clinical deteriolapse may be expected to occur at any time during the Ltion. This process has similarities to cases of pheno~ first 12 months (20, 21 ). 
